- Meeting abstract
- Open Access
The role of sentinel node biopsy (SNB) in elderly breast cancer patients
© Benevento et al; licensee BioMed Central Ltd. 2010
- Published: 19 May 2010
- Breast Cancer
- Sentinel Node Biopsy
- Axillary Lymph Node Dissection
- Comprehensive Geriatric Assessment
- Node Negative Patient
Aged patients suffering from breast cancer are often “undertreated” because of their presumed shorter life expectancy, increasing comorbidity, and favorable tumor biology.
The Consensus Conference Panel of Philadelphia recommends SNB in patients with breast tumours ≤3 cm., although some authors have reported that this technique is reliable also in elderly patients with larger tumors.
The aim of this study was to assess the safety of the procedure as well as the rate of axillary recurrences after SNB in a series of old population.
Between June 2007 and March 2009, we observed 122 female patients over 70 years old (range 70-85 years; mean age 75.6 years) with breast cancer.
A comprehensive geriatric assessment (CGA) was administered before and after surgery to assess the functional status as well as comorbidity and quality of life.
After CGA and anaesthesiologic examination, a total of 108 (88.5%) of 122 patients were candidates for surgery, but 14 patients refused it. So 96 patients (89%) were operated on.
Breast-conserving surgery was performed in 60 (62.5%) of the 96 patients, while a radical mastectomy was performed in 36 (37%) patients.
A total of 77 (80.2%) of 96 patients underwent SNB; 30 (31%) had positive SNB (N+) and underwent axillary lymphadenectomy. In the remaining 47 patients (49%), SNB was negative (N0) for metastasis. At present, no axillary recurrence was observed in the group of sentinel node negative patients.
Surgery is still the treatment of choice for primary breast cancer in the geriatric population , in the context of a multidisciplinary approach which needs to be adapted to the patient’s health status.
The principles concerning geriatric evaluation in elderly cancer patients before treatment, (CGA) establish the necessity of some form of assessment for all patients aged 70 and older.
The recent trend to substitute SNB can also be called into question, particularly in patients with a clinically negative axilla. There are few reports on the clinical recurrence rate in patients treated with SNB due to the short follow-up. Our study data suggest that SNB, when indicated, gives information about axillary staging, and spares patients aged ≥70 years unnecessary axillary lymph node dissection.
This article is published under license to BioMed Central Ltd.